Dose Reduction <i>versus</i> Dose-interval Prolongation in Eribulin Mesilate Monotherapy in Patients with Metastatic Breast Cancer: A Retrospective Comparative Study-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Dose Reduction versus Dose-interval Prolongation in Eribulin Mesilate Monotherapy in Patients with Metastatic Breast Cancer: A Retrospective Comparative Study

Published:2016-07-01 Issue:7 Volume:136 Page:1023-1029
ISSN:0031-6903
Container-title:YAKUGAKU ZASSHI
language:en
Short-container-title:YAKUGAKU ZASSHI

Author:

Sasaki Toshinori¹²,Oshima Yumiko³²,Mishima Etsuko⁴²,Ban Akiko⁵²,Katsuragawa Kenji⁶²,Nagamatsu Hidetsugu⁴²,Yoshioka Yuki⁵²,Tsukiyama Ikuto⁷²,Hisada Tatsuya⁶²,Itakura Yukari⁸²,Mizutani Mitsuhiro⁹

Affiliation:

1. Department of Pharmacy, Mikawa Breast Cancer Clinic

2. Division of Oncology, Aichi Prefectural Society of Hospital Pharmacists; Nagoya City University Hospital

3. Department of Pharmacy, Ichinomiya Municipal Hospital

4. Department of Pharmacy, Handa City Hospital

5. Department of Pharmacy, Nishichita General Hospital

6. Department of Pharmacy, TOYOTA Memorial Hospital

7. Department of Pharmacy, Aichi Medical University Hospital

8. Department of Pharmacy, Hekinan Municipal Hospital

9. Department of Breast Surgery, Mikawa Breast Cancer Clinic

Publisher

Pharmaceutical Society of Japan

Subject

Pharmaceutical Science,Pharmacology

Link

https://www.jstage.jst.go.jp/article/yakushi/136/7/136_15-00267/_pdf

Reference15 articles.

1. 1) Hortbagyi G. N., N. Engl. J. Med., 339, 974-984 (1998).

2. 2) Greenberg P. A., Hortbagyi G. N., Smith T. L., Ziegler L. D., Frye D. K., Buzdar A. U., J. Clin. Oncol., 14, 2197-2205 (1996).

3. 3) Fossati R., Confalonieri C., Torri V., Ghislandi E., Penna A., Pistotti V., Tinazzi A., Liberati A., J. Clin. Oncol., 16, 3439-3460 (1998).

4. 4) Paterson A. H. G., Szafran O., Cornish F., Lees A. W., Hanson J., Breast Cancer Res. Treat., 1, 357-363 (1981).

5. 5) A'Hern R. P., Smith I. E., Ebbs S. R., Br. J. Cancer, 67, 801-805 (1993).

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Eribulin in breast cancer: Current insights and therapeutic perspectives;World Journal of Experimental Medicine;2024-06-20

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3